

You have already added 0 works in your ORCID record related to the merged Research product.
You have already added 0 works in your ORCID record related to the merged Research product.
<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=undefined&type=result"></script>');
-->
</script>
You have already added 0 works in your ORCID record related to the merged Research product.
You have already added 0 works in your ORCID record related to the merged Research product.
Antibody Characterization Report for Alsin
Antibody Characterization Report for Alsin
Head-to-head comparison of available commercial antibodies against Alsin by immunoblot (Western blot), immunoprecipitation and immunofluorescence. Work reported in this report was supported in part by the ALS-Reproducible Antibody Platform (ALS-RAP). ALS-RAP was created as a public-private partnership by three leading ALS charities: the ALS Association (USA), the Motor Neurone Disease Association (UK), and the ALS Society of Canada.
Alsin, amyotrophic lateral sclerosis, antibody characterization, ALS2, Amyotrophic lateral sclerosis 2 protein, Q96Q42, antibody validation, ALS-RAP
Alsin, amyotrophic lateral sclerosis, antibody characterization, ALS2, Amyotrophic lateral sclerosis 2 protein, Q96Q42, antibody validation, ALS-RAP
17 Research products, page 1 of 2
- 2022IsAmongTopNSimilarDocuments
- 2022IsAmongTopNSimilarDocuments
- 2022IsAmongTopNSimilarDocuments
- 2022IsAmongTopNSimilarDocuments
- 2022IsAmongTopNSimilarDocuments
- 2021IsAmongTopNSimilarDocuments
- 2022IsAmongTopNSimilarDocuments
- 2021IsAmongTopNSimilarDocuments
- 2021IsAmongTopNSimilarDocuments
- 2021IsAmongTopNSimilarDocuments
citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).0 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average visibility views 43 download downloads 38 citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).0 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average Powered byBIP!
- 43views38downloads



Head-to-head comparison of available commercial antibodies against Alsin by immunoblot (Western blot), immunoprecipitation and immunofluorescence. Work reported in this report was supported in part by the ALS-Reproducible Antibody Platform (ALS-RAP). ALS-RAP was created as a public-private partnership by three leading ALS charities: the ALS Association (USA), the Motor Neurone Disease Association (UK), and the ALS Society of Canada.